Healthcare
Sysmex Corporation(SSMXY)
Live Price
Offline$8.62
-2.05% today
1Y Change
-46.90%
Window
Jun 23, 2025 โ Jun 1, 2026
- Market Cap
- $829.76B
- Revenue Growth
- +10.2%
- EPS Growth
- +8.6%
- Dividend Yield
- 2.9%
Coverage: 236 bars ยท Jun 23, 2025 โ Jun 1, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sysmex Corporation (SSMXY) is a Healthcare stock with a market cap of $829.76B and listed on OTC. The stock last traded around $8.62 and down 46.9% across the available one-year price window (Jun 23, 2025 โ Jun 1, 2026). Baseline metrics include revenue growth of +10.2%, EPS growth of +8.6%, a dividend yield of 2.9%. What stands out right now is revenue +10.2%, EPS +8.6%, free cash flow +179.2% with operating margin 14.0% and ROIC 8.1%. The dividend matters to the case here, with a current yield around 2.9%. Valuation is more restrained than many high-expectation growth names at P/E 18.5 and price/sales 1.6. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines SSMXY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.2% vs +7.6% peer median
Operating Margin
Below sector median
+14.0% vs +19.4% peer median
P/E
Below sector median
18.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +10.2% and EPS at +8.6%, with operating margin around 14.0%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.9%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -4.0% | +2.4% | โ |
2026 Feb 12, 2026 | +7.2% | -9.6% | -8.7% | -8.0% |
2025 Nov 5, 2025 | -2.0% | +1.4% | +1.1% | -7.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SSMXY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SSMXY Max Drawdown
-53.33%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SSMXY and SPY.
Company Overview
Sysmex Corporation
Other OTC
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. Sysmex Corporation has a strategic alliance with QIAGEN N.V. for the development and commercialization of cancer companion diagnostics using Plasma-Safe-SeqS technology. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
- Leadership
- Hisashi Ietsugu
- IPO Date
- Oct 17, 2011
- Employees
- 10.0k
- Street Address
- 1-5-1, Wakinohama-Kaigandori
- Mailing
- Kobe, 651-0073
- Region
- Kobe, JP
- Reporting Currency
- USD
- Investor Line
- 81 78 265 0500
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 18.5
- EV/EBITDA
- 7.1
- Price/Sales
- 1.6
- Price/Book
- 1.7
Growth
- Revenue
- +10.2%
- EPS
- +8.6%
- Free Cash Flow
- +179.2%
Profitability
- Gross Margin
- 51.9%
- Operating Margin
- 14.0%
- Net Margin
- 8.9%
- ROE
- 9.4%
- ROIC
- 8.1%
Balance Sheet
- Debt/Equity
- 0.14
- Current Ratio
- 3.33
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.